Three lots of cyclophosphamide for injection, one of the most widely used chemotherapy drugs in the United States, are being recalled nationwide because vials were found to contain particles of steel.
Sunny Pharmtech, Inc., of Taoyuan City, Taiwan, announced the voluntary recall on July 24. It reaches the user level, meaning hospitals, clinics, and pharmacies are being asked to pull the product from their shelves rather than simply stopping distribution. The affected product carries the Long Grove Pharmaceuticals brand name and was distributed by Cardinal Health.
No adverse events or injuries connected to the particles had been reported as of the announcement.
That last fact matters, and so does the reason the recall is serious anyway. This is a drug infused directly into a vein, often into people whose bodies are least able to tolerate a complication.
What Is Being Recalled
Three lots are affected, in two vial sizes.
The 1 gram, 50 mL single-dose vial carries National Drug Code 81298-8112-1 and covers lot C23019V1, expiring October 2026, and lot C24015V1, expiring April 2027. The 2-gram, 100-mL single-dose vial carries NDC 81298-8114-1 and covers lot V24010V1, expiring March 2027.
The product was distributed to wholesalers, distributors, hospitals, and pharmacies between May and October of 2024. All three lots remain within their expiration dates, which is why a recall matters two years later. Vials purchased in 2024 could still be sitting in a clinic's inventory today.
Sunny Pharmtech has notified the FDA and Cardinal Health and is coordinating with Long Grove Pharmaceuticals to reach pharmacies and providers. Facilities holding the product are instructed to stop using and dispensing it immediately, quarantine the affected inventory, and arrange return.
Why the Risk Falls on Facilities Rather Than Patients
This is the part most coverage of drug recalls gets wrong when the drug is an infusion.
Cyclophosphamide for injection is not a prescription you pick up and store at home. It is supplied in vials to hospital and clinic pharmacies, reconstituted and prepared by pharmacy staff, and administered intravenously by clinical teams. Almost no patient has these vials in their possession.
That means the practical action, checking lot numbers and pulling stock, belongs to the pharmacy and the infusion center. There is nothing in a medicine cabinet at home for a patient to inspect.
It also means a patient cannot verify this themselves. What they can do is ask.
What the FDA Notice Says About Risk
The company's risk statement, posted by the FDA, is specific about who is most vulnerable and why.
It states that there is a reasonable probability of serious adverse events, including death, if a patient receives an intravenous infusion of product containing particulate matter. The population identified as most at risk is cancer patients, who the notice says are likely to have multiple pre-existing conditions and may be immunosuppressed from current or prior treatment and from nutritional problems related to their cancer.
For that group, the notice says, "complications can include phlebitis, granuloma, and occlusion or life-threatening thromboembolic events." In plainer terms: inflammation of the vein, a small mass of tissue forming around foreign material, and blockage of a blood vessel, including clots that can travel.
None of that has been reported to have happened. The statement describes what could occur if contaminated product were infused, not what has occurred.
Cyclophosphamide is used across a wide range of cancers, including malignant lymphomas, Hodgkin's disease, multiple myeloma, leukemias, mycosis fungoides, neuroblastoma, ovarian adenocarcinoma, retinoblastoma, and breast carcinoma. It is also approved for pediatric patients with biopsy-proven minimal change nephrotic syndrome who did not respond to or could not tolerate corticosteroid therapy, so the affected population is not only oncology patients.
What Patients and Caregivers Can Reasonably Ask
Do not stop or change treatment because of this recall. The FDA notice is explicit that patients should not stop or alter prescribed treatment without consulting a healthcare professional, and interrupting chemotherapy carries its own risks.
Reasonable questions for an oncology pharmacy or infusion center:
Has the facility checked its cyclophosphamide inventory against the three recalled lot numbers? Any hospital pharmacy will have done this or will do it on request, and asking is not an imposition.
Did any of my previous infusions come from one of these lots? A pharmacy can generally trace which lot was used for a given dose. This is worth asking primarily for peace of mind, since no injuries have been reported.
Is there a supply issue that could delay my next cycle? Three lots from one manufacturer is a small share of the national supply, and a delay is unlikely, but confirming is reasonable if your treatment schedule is tight.
Symptoms that warrant prompt attention after any infusion, recall or not, include pain, redness, swelling, or a hard cord along the vein used for infusion, along with new shortness of breath, chest pain, or swelling in one leg. Report these to your oncology team promptly, and seek emergency care for chest pain or difficulty breathing.
Adverse reactions or quality problems can be reported to FDA's MedWatch program. Consumers with questions can also reach Sunny Pharmtech directly at the contact listed in the FDA notice.
The confirmed situation is a nationwide recall of three lots for steel particulate, with no injuries reported. The people most affected are patients receiving cyclophosphamide infusions and the pharmacies that stock it. The most reasonable action is to ask whether your facility has checked its inventory, and not to alter treatment. The central uncertainty is how much affected product remains in clinic inventories nearly two years after distribution ended.
Frequently Asked Questions
Which lots are recalled? Lot C23019V1 and lot C24015V1 in the 1 gram, 50 mL vial (NDC 81298-8112-1), and lot V24010V1 in the 2 gram, 100 mL vial (NDC 81298-8114-1).
Has anyone been harmed? No adverse events or injuries connected to the particulate matter had been reported as of the July 24 announcement.
Do I have this drug at home? Almost certainly not. Cyclophosphamide for injection is supplied to hospital and clinic pharmacies and administered intravenously by clinical staff, not dispensed to patients.
Should I skip my next treatment? No. The FDA notice specifically says patients should not stop or change prescribed treatment without consulting a healthcare professional. Ask your team rather than acting alone.
What harms does the notice describe? Inflammation of the vein, tissue reaction around foreign material, and blood vessel blockage, including potentially life-threatening clots. These are described as possible risks, not reported events.
Who is considered most at risk? Cancer patients, who the notice says often have multiple pre-existing conditions and may be immunosuppressed from treatment or from nutritional problems related to their cancer.
What should I ask my infusion center? Whether they have checked inventory against the three lot numbers, whether any of your prior doses came from those lots, and whether supply could affect your schedule.
